$OMER

BlackRock (OMER) discloses 5.96M Omeros Corp shares in amended 13G filing

BlackRock, Inc. filed an amended Schedule 13G reporting beneficial ownership of 5,961,792 shares of Omeros Corp common stock, or 8.2% of the outstanding class. The filing shows sole voting power over 5,835,368 shares and sole dispositive power over 5,961,792 shares, with no shared voting or dispositive power.

Original reporting
Published Jul 29, 2026, 7:23 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 30, 2026, 12:18 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$OMER
Neutral
medium confidence
Mentioned
$OMER
Relevance
4/10
alphai data visualization · based on stocktitan.net
Decision brief

The 30-second read

$OMERNeutralLow
01

Why it matters

For Omeros, the key incremental information is BlackRock’s reported 8.2% beneficial ownership and its sole voting and dispositive control over the reported shares. However, the text does not indicate activism, board changes, or a transaction that would directly reset near-term fundamentals.

02

Market read

Traders may monitor for follow-on governance signals, but this specific disclosure alone is unlikely to drive a large repricing without additional catalysts.

03

What to watch

The filing does not specify intent (e.g., activism) or any change in control; traders should avoid extrapolating to governance outcomes without follow-on disclosures (13D, proxy activity).

Relevance 4/10Novelty 4/10Timing: as-of the amended Schedule 13G/A filing date (published 2026-07-29)

Background

Schedule 13G filings disclose beneficial ownership of more than 5% for passive investors; amendments update the reported stake and voting/dispositive powers.

Company-level read

Ticker impact

$OMERNeutralMedium confidence
Context

BlackRock amended its Schedule 13G to report beneficial ownership of 5,961,792 Omeros shares, or 8.2% of the class.

Expected impact

Likely limited near-term impact; any effect would be through sentiment around ownership concentration rather than new fundamentals.

Evidence & confidence

This is a regulatory ownership disclosure (13G/A) with quantified stake and voting/dispositive powers, but it provides no new company-specific catalyst like guidance, deals, or litigation.

Market effects

Minimal sector read-through; this is a single-name ownership disclosure.

None indicated.

None indicated.

Counterpoint

A 13G/A amendment can reflect administrative updates or rebalancing rather than a new conviction, so price reaction may be muted.

Key entities

  • Omeros Corp

    Subject of the amended Schedule 13G/A showing BlackRock’s beneficial ownership of 5,961,792 shares (8.2%).

  • BlackRock, Inc.

    Reporting filer that amended its Schedule 13G to disclose sole voting and dispositive power over the reported Omeros shares.

Related articles

$ENTXMed

Top Biotech Gainers: GOSS To File Seralutinib NDA In Sep, OMER Gains On AZN's Loss, FBRX Acquired

Biotech gainers included Entera Bio (ENTX), up 91% after an oversubscribed private placement expected to raise about $275M. Gossamer Bio (GOSS) rose 47% on plans to file a Seralutinib NDA for PAH in Sept 2026 and regain rights from Chiesi. Forte Biosciences (FBRX) jumped 40% on argenx (ARGX) acquisition for $77/share. Omeros (OMER) gained 16% after AstraZeneca’s Ultomiris failed a Phase 3 endpoint.

$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).

$AVAVMedAI 8/10

Bloomberg: US to purchase anti-drone lasers for $400 million

Bloomberg reports the Pentagon will buy laser-based counter-drone systems from AeroVironment Inc. in a deal valued at at least $400 million. The contract is expected to supply the Army with dozens of Locust systems, described as an AI-enabled laser system for tracking and disabling small and medium UAVs. AeroVironment shares rose 8.1% intraday, according to the report.